INTRODUCTION
• Metyrapone blocks cortisol production by inhibiting 11β-hydroxylation of 11-deoxycortisol, the last step of cortisol synthesis ( Figure 1 ).
1
• Based on observational retrospective studies published over more than 50 years, metyrapone is approved for the treatment of endogenous Cushing's syndrome (CS) in 15 European countries. 2 • PROMPT is the first prospective study to document the safety and efficacy of metyrapone using modern assay techniques. 
METHODS

Patients
• Adult patients with a new diagnosis of endogenous CS of any etiology (except advanced adrenal carcinoma) or recurrent or persistent Cushing's disease (CD) after transsphenoidal surgery (TSS), were eligible if three baseline urinary free cortisol (UFC) values measured over 24 hours were at least 50% above the upper limit of normal (ULN=165 nmol/24h).
Study design (Figure 2)
• The international European Phase III/IV PROMPT study commenced in 2015 (ClinicalTrial.gov registry: NCT02297945).
• • Metyrapone given three or four times daily was individually titrated based on cortisol levels in urine and serum over 12 weeks to achieve normal urine and serum cortisol levels according to a titration scheme ( Figure 2 ).
• After 12 weeks, patients whose mean value of 3 UFCs (mUFC) was less than twice the ULN, continued to receive metyrapone for another 24 weeks ( Figure 2 ).
• Cortisol was measured in a central laboratory by liquid chromatography tandem-mass spectrometry (LC-MS/MS)
method. This assay is used to avoid cross-reactivity of 11-deoxycortisol in cortisol immunoassays. 
ENDPOINTS
• The primary endpoint is to assess the efficacy of metyrapone to normalize mUFC after 12 weeks of treatment.
• Secondary endpoints are: -Assessment of the efficacy of metyrapone to normalize serum and salivary cortisol after 12 weeks and 
STATUS
• The study commenced in 2015 and is ongoing.
• By April 2018, 35 patients were included: 24 women and 11 men, with a mean age of 45 years old (range: 21-73).
• A total of 32 patients had CD and 21 patients had previously undergone TSS (range: 1-3).
• Nine patients discontinued the study at/or after the primary objective endpoint (Week 12) owing to: inefficacy (n=3), mUFC >2 x ULN despite improvement by 70% (n=1), hirsutism (n=1), serious AEs (n=1; severe hypotension, cellulitis, venous thrombosis and renal insufficiency) and decision to undergo TSS despite control with metyrapone (n=3).
• The mean of the mUFC values in the first 28 patients treated over 12 weeks decreased from 860 nmol/24h at baseline to 186 nmol/24h at Week 12 (Figure 3) . 
